secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALUMIS INC. (ALMS)
CIK:        0001847367
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001104659-25-027444
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alumis licenses ESK-001 to Kaken for Japan; $40M upfront/near-term plus $140M milestones
--------------------------------------------------------------------------------

- Alumis receives $20M upfront and $20M co-development payments from Kaken in 2025-2026.
- Kaken gets exclusive rights to develop/commercialize ESK-001 for dermatology in Japan, with options for rheumatology and GI.
- Alumis retains rights outside Japan; Kaken contributes to global development costs.
- Cash runway extended through Phase 3 ONWARD psoriasis topline data readout.
- Tiered royalties on Japan net sales: low double-digits to twenties percent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847367/000110465925027444/0001104659-25-027444-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847367/000110465925027444/tm2510181d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-027444

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer